Role of Pemetrexed in Sdvanced Non-Small-Cell Lung Cancer: Meta-Analysis of Randomized Controlled Trials, with Histology Subgroup Analysis

Alsaleh, Khalid; Quinton, Cindy; Ellis, Peter

doi:10.3747/co.19.891

Cited by 40 publications

(28 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In Asian countries, adenocarcinoma type of lung cancer predominates [7] and various chemotherapeutic regimens are available for treating adenocarcinoma. Pemetrexed containing chemotherapy regimens have gained importance in recent past because of favorable response, improved patient survival and better tolerability over taxanes and another group of drugs [4]. Bone is the common site of metastasis owing to high blood flow in red marrow with primary cancers being prostate, breast, kidney and lung [5] and incidence of lung cancer metastasizing to bone is found to be high [5].…”

Section: Discussionmentioning

confidence: 99%

“…Among the various histological subtypes of lung cancer, trends show increased incidence of adenocarcinoma among both men and women [3]. Pemetrexed-containing chemotherapeutic regimens are now widely used compared to taxanes, platinum-based, and other chemotherapeutic agents [4]. Bone is a common site of metastasis and incidence of lung cancer metastasizing to bone is around 36% [5].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Zoledronic Acid: A Mischievous Suspect for Liver Injury

Gill

Balaji

Kumari

et al. 2016

Asian J Pharm Clin Res

View full text Add to dashboard Cite

A 47-year-old male diagnosed as adenocarcinoma of the lung and received 8 cycles of chemotherapy comprising intravenous administration of cisplatin 125 mg, pemetrexed 850 mg along with zoledronic acid 4 mg. After the completion of the 8 th cycle, the liver enzymes were found to be markedly elevated, evincing zoledronic acid as the cause for hepatotoxicity. The case details were taken from the patient's medical record along with the biochemical test reports and radiographic images. The causal association was confirmed using Naranjo's algorithm and Roussel Uclaf Causality Assessment Method (RUCAM). After the uneventful chemotherapy, patient's liver function tests (LFT) were abnormal. There was an elevation in the aspartate aminotransferase, alanine transaminase, alkaline phosphatase, and direct bilirubin. The causal relationship was established using Naranjo's algorithm (score-6) and RUCAM (score-5), displayed a "probable" and "possible" association. Hartwig's severity scale and Thornton's preventability scale displayed the adverse drug reaction to being moderately severe and not preventable, respectively. The zoledronic acid was stopped and never readministered. The LFTs assumed normal after a span of 2 months. The mechanism underlying hepatotoxicity due to zoledronic acid remains elusive. Zoledronic acid can induce acute phase response mediated by active production of interleukin-6, tumor necrosis factor alpha, and pro-inflammatory cytokines from the T-cells and macrophages. Vigilant monitoring along with timely assessment and management can prevent the occurrence of irreversible liver damage. Henceforth, we would like to report the rare incidence of drug induced hepatic damage due to zoledronic acid. Henceforth, we would like to report the rare incidence of drug induced hepatic damage due to zoledronic acid.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Zoledronic Acid: A Mischievous Suspect for Liver Injury

Gill

Balaji

Kumari

et al. 2016

Asian J Pharm Clin Res

View full text Add to dashboard Cite

show abstract

“…Multipl intraselüler hedefleri olan bir antifolat ajan pemetreksed ile yapılan randomize çalışmalarda bu ilacın nonskuamoz hücre tipinde daha etkili olduğu gösterilmiştir. Yakın zamanda yapılan bir meta-analiz de bu sonucu desteklemektedir (12). Pemetreksed birinci basamak tedavide sisplatinle kombine, ikinci basamak tedavide tek ajan olarak nonskuamoz KHDAK'de endikasyon almıştır (3,4).…”

Section: Discussionunclassified

A case of locally advanced non-small cell lung cancer with an unusual decision of treatment, the result of treatment and course

Akpınar¹,

Hoşgün²,

Gülhan³

2013

Respir Case Rep

View full text Add to dashboard Cite

Küçük hücreli dışı akciğer kanseri (KHDAK) tüm akciğer kanserli olguların % 85'inden fazlasını oluşturur. Bu olguların yaklaşık üçte biri lokal ileri evre olgulardır. Bu evredeki olgular çok heterojen bir gruptur ve bu nedenle tedavi planlaması daha zor ve özelliklidir. Bu olgularda genel tedavi yaklaşımı kemoradyoterapi olmakla beraber, tedavi kararı olgu bazında dikkatle ele alınmalıdır. Pemetreksed, timidilat sentazın ve diğer folat bağımlı enzimlerin potent inhibitörü olan sitotoksik bir ajandır. Non-homogeneous KHDAK'de, faz III çalışmalarla, önce ikinci daha sonra birinci basamak ve son olarak da idame tedavide etkinliği gösterilmiştir. Bu makalede, adenokarsinom hücre tipine sahip, klinik evresi IIIA3 olarak belirlenen, multipl komorbiditeleri olan, bu nedenle tedavi planlaması başlangıçta ve progresyonda güçlükler taşıyan, buna karşın tanı konduktan sonra 4 yıl geçmesine rağmen halen metabolik tam yanıtta olan bir KHDAK olgusu sunulmuştur. Tedavisi standart olmayan lokal ileri evre olgularda tedavi yaklaşımı gözden geçirilmiş ve ikinci basamakda pemetreksed tedavisine uzun süreli metabolik tam yanıt vurgulanmıştır. Anahtar Sözcükler: Küçük hücre dışı akciğer kanseri, pemetrexed, sağkalım, tedavi.Non-small cell lung cancer (NSCLC) constitutes 85% of lung cancer. One-third of these cases are locally advanced. The patients are heterogeneous in this state, and thus their plan of treatment is unique. Although standard treatment is combined chemoradiotherapy in these patients, the decision of treatment should be evaluated carefully for each patient. Pemetrexed is a cytotoxic agent, potent inhibitor of thymidylate synthetase and other folate-dependent enzymes. Phase III studies showed its effectiveness in the first and second line treatment of non-squamous NSCLC. In this report, a case of NSCLC with adenocarcinoma subtype who staged clinically as stage IIIA3 and had multiple co-morbidities was presented. For this reason, his initial treatment plan and treatment in progression resulted in difficulties. Nevertheless, the patient has maintained complete metabolic response after four years. The treatment approach to this group of patients was overviewed and long-term and complete response to pemetrexed in second-line treatment was emphasized.

show abstract

“…Non-small cell lung cancer (NSCLC) constitutes more than 80% of lung cancer cases, and the incidence of NSCLC is gradually increasing (2). Despite recent advances made in clinical and experimental oncology, the prognosis of NSCLC is still unfavorable, with a 5-year overall survival rate of only around 15% (3).…”

Section: Introductionmentioning

confidence: 99%

MicroRNAs in Body Fluids as Biomarkers for Non-Small Cell Lung Cancer: A Systematic Review

Huang

Deng

et al. 2014

Technol Cancer Res Treat

View full text Add to dashboard Cite

Non-small cell lung cancer (NSCLC) is one of the most common life-threatening malignant tumors. A test for early diagnosis of NSCLC needs to be not too invasive and not too heavy a burden for weakened patients. A series of studies reported various microRNAs (miRNAs) could be novel serum biomarkers for NSCLC. However, the diagnostic ability of different miRNA biomarkers varies among the reports. The goal of this study was to perform a systematic review to examine the effect of miRNAs on NSCLC-related outcomes. We system- The range of diagnostic odds ratio (DOR) was 6.52983.38. The current evidence indicates that miRNAs in body fluids show high accuracy in identifying NSCLC, and could be a useful screening tool for diagnosing NSCLC patients.

show abstract

Role of Pemetrexed in Sdvanced Non-Small-Cell Lung Cancer: Meta-Analysis of Randomized Controlled Trials, with Histology Subgroup Analysis

Cited by 40 publications

References 26 publications

Zoledronic Acid: A Mischievous Suspect for Liver Injury

Zoledronic Acid: A Mischievous Suspect for Liver Injury

A case of locally advanced non-small cell lung cancer with an unusual decision of treatment, the result of treatment and course

MicroRNAs in Body Fluids as Biomarkers for Non-Small Cell Lung Cancer: A Systematic Review

Contact Info

Product

Resources

About